Global Influenza Treatment Market is valued approximately USD 5.84 billion in 2022 and is anticipated to grow with a healthy growth rate of more than 1.18% over the forecast period 2023-2030. Influenza treatment refers to the therapeutic interventions employed to alleviate the symptoms and complications associated with influenza, a highly contagious respiratory viral infection commonly known as the flu. The primary goals of influenza treatment are to reduce the severity and duration of symptoms, prevent complications, and limit the spread of the virus. The Influenza Treatment market is expanding because of factors such as increased prevalence of contagious respiratory illness, emerging prevalence of seasonal flu and rising drug approval activities.
As per the CDC, the impact of influenza in the United States is substantial, with an estimated 27 to 54 million cases, 300,000 to 650,000 hospitalizations, and 19,000 to 58,000 deaths annually between 2022 and 2023. Preliminary data also reveals around 9 million symptomatic cases, 4 million medical visits, 100,000 hospitalizations, and 5,000 deaths from 2021 to 2022. These figures underscore the significant public health challenge posed by influenza, emphasizing the need for effective preventive measures and treatments to mitigate its impact on individuals and healthcare systems. Thus rising prevalence of seasonal flu is driving the market growth. In addition, rising investment in research and development activities and increased public awareness about the severity of influenza is creating new opportunities for the market growth. However, the high cost of Influenza Treatment stifles market growth throughout the forecast period of 2023-2030.
The key regions considered for the Global Influenza Treatment Market study includes Asia Pacific, North America, Europe, Latin America, and Middle East & Africa. North America dominated the market in 2022 owing to the dominance of key market players, rising disease prevalence, rising drug development activities in the region. Asia Pacific is expected to grow at a fastest rate during the forecast period, owing to factors such as rising target populations, an increase in the number of collaborations for durg development, rising healthcare expenditure, and active participation of government and in the market space.
Major market player included in this report are:
- NATCO Pharma Limited
- Novartis AG
- F. Hoffmann-La Roche Ltd
- BioCryst Pharmaceuticals, Inc.
- Sanofi
- GSK plc.
- Viatris Inc. (MYLAN)
- Teva Pharmaceutical Industries Ltd.
- Daiichi Sankyo Company, Limited.
- AstraZeneca
Recent Developments in the Market:
- In July 2023, Shionogi & Co., Ltd. has disclosed the submission of a supplemental New Drug Application (sNDA) for Xofluza. This application pertains to the pediatric population, specifically for children aged 5 to 12 years, and seeks approval for the use of Xofluza in both post-exposure prophylaxis and the treatment of influenza virus infections.
- In April 2023, Nanjing Zenshine Pharmaceuticals revealed positive outcomes from the phase II trials of ZX-7101A, specifically designed to address acute uncomplicated influenza in adults
Global Influenza Treatment Market Report Scope:
- Historical Data: 2020 - 2021
- Base Year for Estimation: 2022
- Forecast period: 2023-2030
- Report Coverage: Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
- Segments Covered - Treatment, Rout of Administration, Distribution Channel, Region
- Regional Scope: North America; Europe; Asia Pacific; Latin America; Middle East & Africa
- Customization Scope: Free report customization (equivalent up to 8 analyst's working hours) with purchase. Addition or alteration to country, regional & segment scope*
The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.
The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below.
By Treatment:
- Peramivir
- Zanamivir
- Baloxavir Marboxil
- Oseltamivir Phosphate
- Others
By Route of Administration:
By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
By Region:
- North America
- U.S.
- Canada
- Europe
- UK
- Germany
- France
- Spain
- Italy
- ROE
- Asia Pacific
- China
- India
- Japan
- Australia
- South Korea
- RoAPAC
- Latin America
- Brazil
- Mexico
- Middle East & Africa
- Saudi Arabia
- South Africa
- Rest of Middle East & Africa
Table of Contents
Chapter 1. Executive Summary
- 1.1. Market Snapshot
- 1.2. Global & Segmental Market Estimates & Forecasts, 2020-2030 (USD Billion)
- 1.2.1. Influenza Treatment Market, by region, 2020-2030 (USD Billion)
- 1.2.2. Influenza Treatment Market, by Treatment, 2020-2030 (USD Billion)
- 1.2.3. Influenza Treatment Market, by Route of Administration, 2020-2030 (USD Billion)
- 1.2.4. Influenza Treatment Market, by Distribution Channel, 2020-2030 (USD Billion)
- 1.3. Key Trends
- 1.4. Estimation Methodology
- 1.5. Research Assumption
Chapter 2. Global Influenza Treatment Market Definition and Scope
- 2.1. Objective of the Study
- 2.2. Market Definition & Scope
- 2.2.1. Industry Evolution
- 2.2.2. Scope of the Study
- 2.3. Years Considered for the Study
- 2.4. Currency Conversion Rates
Chapter 3. Global Influenza Treatment Market Dynamics
- 3.1. Influenza Treatment Market Impact Analysis (2020-2030)
- 3.1.1. Market Drivers
- 3.1.1.1. Increased prevalence of contagious respiratory illness
- 3.1.1.2. Emerging prevalence of seasonal flu
- 3.1.1.3. Rising drug approval activities
- 3.1.2. Market Challenges
- 3.1.2.1. High Cost of Influenza Treatment
- 3.1.2.2. Stringent regulatory processes and delays in drug approvals
- 3.1.3. Market Opportunities
- 3.1.3.1. Rising investment in research and development activities
- 3.1.3.2. Increased public awareness about the severity of influenza
Chapter 4. Global Influenza Treatment Market: Industry Analysis
- 4.1. Porter's 5 Force Model
- 4.1.1. Bargaining Power of Suppliers
- 4.1.2. Bargaining Power of Buyers
- 4.1.3. Threat of New Entrants
- 4.1.4. Threat of Substitutes
- 4.1.5. Competitive Rivalry
- 4.2. Porter's 5 Force Impact Analysis
- 4.3. PEST Analysis
- 4.3.1. Political
- 4.3.2. Economic
- 4.3.3. Social
- 4.3.4. Technological
- 4.3.5. Environmental
- 4.3.6. Legal
- 4.4. Top investment opportunity
- 4.5. Top winning strategies
- 4.6. COVID-19 Impact Analysis
- 4.7. Disruptive Trends
- 4.8. Industry Expert Perspective
- 4.9. Analyst Recommendation & Conclusion
Chapter 5. Global Influenza Treatment Market, by Treatment
- 5.1. Market Snapshot
- 5.2. Global Influenza Treatment Market by Treatment, Performance - Potential Analysis
- 5.3. Global Influenza Treatment Market Estimates & Forecasts by Treatment 2020-2030 (USD Billion)
- 5.4. Influenza Treatment Market, Sub Segment Analysis
- 5.4.1. Peramivir
- 5.4.2. Zanamivir
- 5.4.3. Baloxavir Marboxil
- 5.4.4. Oseltamivir Phosphate
- 5.4.5. Others
Chapter 6. Global Influenza Treatment Market, by Route of Administration
- 6.1. Market Snapshot
- 6.2. Global Influenza Treatment Market by Route of Administration, Performance - Potential Analysis
- 6.3. Global Influenza Treatment Market Estimates & Forecasts by Route of Administration 2020-2030 (USD Billion)
- 6.4. Influenza Treatment Market, Sub Segment Analysis
- 6.4.1. Oral
- 6.4.2. Others
Chapter 7. Global Influenza Treatment Market, by Distribution Channel
- 7.1. Market Snapshot
- 7.2. Global Influenza Treatment Market by Distribution Channel, Performance - Potential Analysis
- 7.3. Global Influenza Treatment Market Estimates & Forecasts by Distribution Channel 2020-2030 (USD Billion)
- 7.4. Influenza Treatment Market, Sub Segment Analysis
- 7.4.1. Hospital Pharmacies
- 7.4.2. Retail Pharmacies
- 7.4.3. Online Pharmacies
Chapter 8. Global Influenza Treatment Market, Regional Analysis
- 8.1. Top Leading Countries
- 8.2. Top Emerging Countries
- 8.3. Influenza Treatment Market, Regional Market Snapshot
- 8.4. North America Influenza Treatment Market
- 8.4.1. U.S. Influenza Treatment Market
- 8.4.1.1. Treatment breakdown estimates & forecasts, 2020-2030
- 8.4.1.2. Route of Administration breakdown estimates & forecasts, 2020-2030
- 8.4.1.3. Distribution Channel breakdown estimates & forecasts, 2020-2030
- 8.4.2. Canada Influenza Treatment Market
- 8.5. Europe Influenza Treatment Market Snapshot
- 8.5.1. U.K. Influenza Treatment Market
- 8.5.2. Germany Influenza Treatment Market
- 8.5.3. France Influenza Treatment Market
- 8.5.4. Spain Influenza Treatment Market
- 8.5.5. Italy Influenza Treatment Market
- 8.5.6. Rest of Europe Influenza Treatment Market
- 8.6. Asia-Pacific Influenza Treatment Market Snapshot
- 8.6.1. China Influenza Treatment Market
- 8.6.2. India Influenza Treatment Market
- 8.6.3. Japan Influenza Treatment Market
- 8.6.4. Australia Influenza Treatment Market
- 8.6.5. South Korea Influenza Treatment Market
- 8.6.6. Rest of Asia Pacific Influenza Treatment Market
- 8.7. Latin America Influenza Treatment Market Snapshot
- 8.7.1. Brazil Influenza Treatment Market
- 8.7.2. Mexico Influenza Treatment Market
- 8.8. Middle East & Africa Influenza Treatment Market
- 8.8.1. Saudi Arabia Influenza Treatment Market
- 8.8.2. South Africa Influenza Treatment Market
- 8.8.3. Rest of Middle East & Africa Influenza Treatment Market
Chapter 9. Competitive Intelligence
- 9.1. Key Company SWOT Analysis
- 9.1.1. Company 1
- 9.1.2. Company 2
- 9.1.3. Company 3
- 9.2. Top Market Strategies
- 9.3. Company Profiles
- 9.3.1. NATCO Pharma Limited
- 9.3.1.1. Key Information
- 9.3.1.2. Overview
- 9.3.1.3. Financial (Subject to Data Availability)
- 9.3.1.4. Product Summary
- 9.3.1.5. Recent Developments
- 9.3.2. Novartis AG
- 9.3.3. F. Hoffmann-La Roche Ltd
- 9.3.4. BioCryst Pharmaceuticals, Inc.
- 9.3.5. Sanofi S.A
- 9.3.6. GSK plc.
- 9.3.7. Viatris Inc. (MYLAN)
- 9.3.8. Teva Pharmaceutical Industries Ltd.
- 9.3.9. Daiichi Sankyo Company, Limited.
- 9.3.10. AstraZeneca
Chapter 10. Research Process
- 10.1. Research Process
- 10.1.1. Data Mining
- 10.1.2. Analysis
- 10.1.3. Market Estimation
- 10.1.4. Validation
- 10.1.5. Publishing
- 10.2. Research Attributes
- 10.3. Research Assumption